Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 2/20 | 0.63 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.63 |
| ▸ | SIGMAR1 | Q99720 | 9/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | DRD4 | P21917 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | CCR3 | P51677 | 1/20 | 0.48 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17339771 | 0.91 | CCR3 (0.53) | GRIN1GRIN2ASIGMAR1DRD2DRD4 | |
| SCHEMBL17339770 | 0.81 | KCNH2 (0.67) | SIGMAR1DRD2DRD4DRD3HTR2A | |
| SCHEMBL8091246 | 0.80 | SIGMAR1 (0.79) | SIGMAR1DRD2DRD4DRD3KCNH2 | |
| SCHEMBL10725426 | 0.79 | ADRB2 (0.59) | DRD2DRD4DRD3ADRB2ADRB1 | |
| SCHEMBL10725397 | 0.79 | ADRB2 (0.59) | DRD2DRD4DRD3ADRB2ADRB1 | |
| SCHEMBL10725416 | 0.79 | ADRB2 (0.59) | DRD2DRD4DRD3ADRB2ADRB1 | |
| SCHEMBL8273956 | 0.79 | TDP1 (0.54) | GRIN1GRIN2ASIGMAR1ADRB2ADRB1 | |
| SCHEMBL17340067 | 0.78 | KCNH2 (0.58) | SIGMAR1DRD2DRD4DRD3KCNH2 | |
| SCHEMBL17753544 | 0.77 | CHRM2 (0.63) | GRIN1GRIN2ASIGMAR1HTR2AKCNH2 | |
| SCHEMBL9973184 | 0.76 | DRD2 (0.50) | SIGMAR1DRD2DRD4DRD3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160136115-A1 | T TYPE CALCIUM CHANNEL INHIBITORS | UNIVERSITY OF VIRGINIA | 2016-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160136115-A1 | T TYPE CALCIUM CHANNEL INHIBITORS | CACNA1H, CACNA1I, CACNA1G | GRIN1 850/4885GRIN2A 1714/4885SIGMAR1 1869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.